<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377936</url>
  </required_header>
  <id_info>
    <org_study_id>CT4001</org_study_id>
    <secondary_id>EudraCT No.: 2005-000666-39</secondary_id>
    <nct_id>NCT00377936</nct_id>
  </id_info>
  <brief_title>EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas</brief_title>
  <official_title>A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intention of this trial is to evaluate safety and efficacy of a combination treatment of
      EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Median</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month-survival-rate</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Median</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and percentage of patients with Adverse Events</measure>
    <time_frame>28 days after last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant abnormal laboratory values</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Metastasis</condition>
  <condition>Pancreas Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTag-1 + Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTag-1 + Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EndoTag-1 + Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine alone</intervention_name>
    <description>Gemcitabine monotherapy 1000 mg/m2 weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1 and Gemcitabine</intervention_name>
    <description>EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1 and Gemcitabine</intervention_name>
    <description>EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EndoTAG-1 and Gemcitabine</intervention_name>
    <description>EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inoperable adenocarcinoma of the pancreas

          -  Histologic or cytologic confirmation

          -  At least 18 years of age

        Exclusion Criteria:

          -  Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment

          -  Major surgery within 4 weeks prior to enrollment

          -  Major cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Löhr, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <last_update_submitted>November 13, 2008</last_update_submitted>
  <last_update_submitted_qc>November 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Susanne Kienzle-Horn / Clinical Trial Manager</name_title>
    <organization>MediGene</organization>
  </responsible_party>
  <keyword>Adenocarcinoma of the pancreas</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

